ライフサイエンスコーパス: hyperinflation

1 n atria and the diaphragm and, therefore, by hyperinflation.

2 iratory muscle function, and reduces dynamic hyperinflation.

3 ecrease) and severe (23% decrease) levels of hyperinflation.

4 ociated with higher lung volumes, suggesting hyperinflation.

5 scaffolds in patients with emphysema-related hyperinflation.

6 rway scaffolds in treating emphysema-related hyperinflation.

7 metronome-paced tachypnea to induce dynamic hyperinflation.

8 view the available literature on spontaneous hyperinflation.

9 ional ventilation in patients with COPD with hyperinflation.

10 s in patients with emphysema and severe lung hyperinflation.

11 ong-acting muscarinic antagonists, to reduce hyperinflation.

12 activation were elevated in severe COPD and hyperinflation.

13 life for patients with severe emphysema and hyperinflation.

14 tment of patients with severe emphysema with hyperinflation.

15 FL and tidal atelectasis, without increasing hyperinflation.

16 ury when pneumonia/sepsis is coupled to lung hyperinflation.

17 strate prominent peribronchial markings with hyperinflation.

18 gical changes, especially the development of hyperinflation.

19 nd prolong exercise time by reducing dynamic hyperinflation.

20 ed with the degree of airflow limitation and hyperinflation.

21 o impaired diaphragm function resulting from hyperinflation.

22 low an estimation of the degree of pulmonary hyperinflation.

23 nd lung volumes showed a slight worsening in hyperinflation.

24 apping and differentiation from compensatory hyperinflation.

25 /- 132 grams; P < 0.001) and increased tidal-hyperinflation (0.41 +/- 0.26 to 0.57 +/- 0.30%; P = 0.0

26 veloped native lung complications (excluding hyperinflation) 0-58 months (mean, 17 months) after tran

27 ssure levels were applied in a random order: hyperinflation, 6 cm H2O above; open lung approach, 2 cm

28 weakness but without airflow obstruction or hyperinflation, a group that would ideally define the ro

29 As a measure of significant hyperinflation, a vertical P axis had a sensitivity of 8

30 genic diet was injured by repetitive balloon hyperinflations, a procedure that rapidly yields complex

31 reversibility (P = 0.01), and improvement in hyperinflation after corticosteroid treatment (P = 0.019

32 We conclude that LVRS, by reducing hyperinflation, air trapping, and improving respiratory

33 by expiratory muscle contraction and dynamic hyperinflation, all increasing pulmonary vascular pressu

34 Hyperinflation alone did not produce tightness or effort

35 re must be taken to avoid augmenting dynamic hyperinflation and acid/base disturbances resulting from

36 elation to vital capacity and to markers for hyperinflation and airway obstruction were found in pati

37 trol subjects, there was significant dynamic hyperinflation and greater tidal volume constraints (P<0

38 and lung aeration but may result in alveolar hyperinflation and hemodynamic alterations.

39 wn about the molecular mechanisms underlying hyperinflation and how inhaled corticosteroids (ICS) aff

40 ronome-paced tachypnea (MPT)-induced dynamic hyperinflation and its relationship with chronic obstruc

41 tment of patients with emphysema with severe hyperinflation and less parenchymal destruction.

42 These included effects on lung hyperinflation and mechanical stress, inflammation, exce

43 ogether, these findings suggest that dynamic hyperinflation and not muscle-based factors dictate the

44 rflow obstruction that leads to dynamic lung hyperinflation and reduced ventilatory response to exerc

45 pulmonary hypertension is induced by airway hyperinflation and supraphysiologic lung volumes.

46 constriction with subsequent effects on lung hyperinflation (and possibly pulmonary circulation) can

47 olume was increased to achieve 25% (moderate hyperinflation) and 50% (severe hyperinflation) incremen

48 ts were 57 +/- 8 yr of age with severe COPD, hyperinflation, and air trapping (FEV1, 0.73 +/- 0.2 L;

49 h of anesthesia and muscle rigidity, gastric hyperinflation, and alveolar collapse) require urgent re

50 d with reduced FEV1 to FVC ratio (FEV1/FVC), hyperinflation, and alveolar enlargement, but little is

51 ay remodeling, more small airway disease and hyperinflation, and less pointwise regional change in lu

52 a coalescence of mechanical forces, such as hyperinflation, and more recently recognized cellular an

53 1 s (FEV1) between 20% and 45%, substantial hyperinflation, and post-rehabilitation 6-min walk test

54 cteristic small airways dysfunction, dynamic hyperinflation, and pulmonary gas exchange abnormalities

55 blue plays a role in preventing spontaneous hyperinflation, and review the available literature on s

56 OPD are due to reduction of lung resistance, hyperinflation, and TGC.

57 treatment on both lung function measures of hyperinflation, and the nasal epithelial gene-expression

58 se tolerance with COPD is limited by dynamic hyperinflation; and (2) cyclically lower (50%) effort in

59 t the hypothesis that airflow limitation and hyperinflation are associated with the duration of asthm

60 e of advanced emphysematous lung disease and hyperinflation are optimal candidates for lung-volume-re

61 Pulmonary hyperinflation, as measured by residual lung volume or r

62 Dynamic hyperinflation (assessed by changes from baseline in ins

63 ratory rate (i.e., less reduction in dynamic hyperinflation at a lower respiratory rate).

64 Patients exhibited less dynamic hyperinflation at isotime points with spinal anesthesia.

65 ucible quantification of MPT-induced dynamic hyperinflation at real-time cine pulmonary MRI, with gre

66 ed at baseline and after moderate and severe hyperinflation, both before and after nitric oxide admin

67 rway scaffold was designed to alleviate lung hyperinflation by connecting emphysematous parenchyma wi

68 The animal model displayed hyperinflation (change in total lung capacity +8%; chang

69 d mechanical ventilation, without increasing hyperinflation.Conclusions: The expiratory modulation in

70 Hyperinflation contributes to dyspnea intensity in COPD.

71 Lower forced expiratory volume, PA:A>1, and hyperinflation correlated with reduced RV ejection fract

72 included patients with emphysema and severe hyperinflation (defined by a baseline residual volume >1

73 aluated the prevalence and impact of dynamic hyperinflation (DH) in LAM.

74 Dynamic hyperinflation (DH) is a major pathophysiologic conseque

75 ntragastric balloons with gastric aspirates, hyperinflation did not occur, and other factors may be i

76 BLVR aims to decrease the extent of hyperinflation due to emphysema and result in a benefici

77 In 12 patients we also quantified dynamic hyperinflation (end-expiratory and end-inspiratory lung

78 rves, along with regional recruitment versus hyperinflation evidence from computed tomography and ele

79 ere 58 +/- 8 yr of age, with severe COPD and hyperinflation (FEV1 = 0.68 +/- 0.23 L, FVC = 2.56 +/- 7

80 ere 58 +/- 8 yr of age, with severe COPD and hyperinflation (FEV1, 0.69 +/- 0.21 L; RV, 4.7 +/- 1.4 L

81 ons were observed between Tw Pdi and dynamic hyperinflation (FRC: r = -0.65, P = 0.005) and arterial

82 regions suffering tidal recruitment or tidal hyperinflation had [(18)F]fluoro-2-deoxy-D-glucose uptak

83 sponder rates, target lobe volume reduction, hyperinflation, health status, dyspnea, and exercise cap

84 nd distal airways and may induce significant hyperinflation (HI).

85 itive end-expiratory pressure setting limits hyperinflation in acute lung injury, but may not provide

86 are palliative treatments aimed at reducing hyperinflation in advanced emphysema.

87 ge analysis of ventilation inhomogeneity and hyperinflation in CF compared with PFT.

88 lator is highly sensitive and predictive for hyperinflation in children.

89 Pulmonary hyperinflation in chronic obstructive pulmonary disease

90 ime cine pulmonary MRI, with greater dynamic hyperinflation in participants with more severe COPD.

91 Rationale: Pulmonary hyperinflation in patients with chronic obstructive pulm

92 es is a treatment option to reduce pulmonary hyperinflation in patients with severe emphysema.

93 ngation of expiratory time decreases dynamic hyperinflation in patients with status asthmaticus, as e

94 ncluded in multivariate regression analysis, hyperinflation (increased thoracic gas volume) was the p

95 s of lung elastic recoil resulting in marked hyperinflation, increased TLC, and decreased Pdi and exp

96 5% (moderate hyperinflation) and 50% (severe hyperinflation) increments in pulmonary vascular resista

97 oxide at baseline (43% decrease) and during hyperinflation induced pulmonary hypertension at both mo

98 mote ventilator-induced lung injury, dynamic hyperinflation, ineffective efforts, and respiratory alk

99 d scan-rescan agreement for EELV and dynamic hyperinflation (intraclass correlation coefficient, 0.99

100 Spontaneous hyperinflation is reported to the Food and Drug Administ

101 easured ventilation, cardiac output, dynamic hyperinflation, local muscle oxygenation, blood lactate

102 nd CLE), IE was associated with less dynamic hyperinflation, lower blood lactate concentration, and g

103 ameliorated experimental ventilator-induced hyperinflation lung injury as determined by pulmonary ca

104 in severe asthma, and that marked pulmonary hyperinflation may be present despite low measured auto-

105 s, although reduction of lung resistance and hyperinflation may result in improved dyspnea with a bro

106 ss to end-diastolic volume (P=0.02) and with hyperinflation measured as residual volume to total lung

107 and 3) reduce tidal atelectasis, preventing hyperinflation.Methods: Three positive end-expiratory pr

108 ty that effects of LABA/LAMA combinations on hyperinflation, mucociliary clearance, and symptom sever

109 1 was prominent peribronchial markings with hyperinflation (n = 17), whereas the most common finding

110 In patients with compensatory hyperinflation (n = 4), mean lung attenuation was -664 H

111 tment and decreases alveolar instability and hyperinflation observed at high PEEP in patients with AR

112 +/- 141 grams; P = 0.028) and reduced tidal hyperinflation observed at PEEP 15 in supine patients (0

113 d at the prealveolar stage with compensatory hyperinflation of immature saccules.

114 y obstruction secondary to emphysema, marked hyperinflation of the chest wall, and regional heterogen

115 (COPD); however, the effect of reduced lung hyperinflation on PMBF remains unknown.

116 were elevated in severe COPD (P = 0.003) and hyperinflation (P = 0.001).

117 = -0.15 [95% CI = -0.26 to -0.05]; P < .01), hyperinflation percent (B = -0.25 [95% CI = -0.41 to -0.

118 l [CI]: 0.21, 0.91), residual volume (static hyperinflation, r = -0.8; 95% CI: -0.94, 0.42), and forc

119 We recruited 315 patients who had severe hyperinflation (ratio of residual volume [RV] to total l

120 xercise tolerance in patients with pulmonary hyperinflation related to advanced emphysema.

121 been reported as a compensatory response to hyperinflation-related diaphragmatic dysfunction.

122 Rates of hyperinflation remain under-reported in the literature.

123 th COPD, stable cardiovascular function, and hyperinflation (residual volume > 135% predicted).

124 d, FEF(25-75%) 11.0 +/- 4.5% predicted), and hyperinflation (residual volume [RV] 341.8 +/- 75.8% pre

125 roponin I, airflow limitation (FEV(1)), lung hyperinflation (residual volume), and gas transfer capac

126 oughout expiration, the reduction in dynamic hyperinflation resulting from a given prolongation of ex

127 With the exception of dynamic hyperinflation states, it is reasonable to assume that n

128 e and for up to 3 h after repetitive balloon hyperinflations sufficient to disrupt the internal elast

129 Of 27 subjects with moderate or severe hyperinflation (TGV > or = 130% predicted), 23 (85%) had

130 The hyperinflation that accompanies diseases of the airways

131 ay not always reflect the changes in dynamic hyperinflation that result from prolongation of expirato

132 EV1) of less than 50% predicted, significant hyperinflation (total lung capacity >100% and residual v

133 Despite hyperinflation, transdiaphragmatic pressures and strengt

134 Among patients with emphysema and severe hyperinflation treated for 12 months, the use of endobro

135 Conclusions: We found that reduction of hyperinflation using BLVR with endobronchial valves sign

136 Native lung hyperinflation was associated with BLAD in obstructive d

137 Dynamic hyperinflation was associated with COPD severity (P tren

138 Hyperinflation was defined as residual volume/total lung

139 Dynamic hyperinflation was evaluated as the increase in end-expi

140 imit of tolerance for each modality, dynamic hyperinflation was not different between IE and CLE, whi

141 Hyperinflation was present at residual volume (RV), FRC,

142 Marked hyperinflation was present in all 10 patients studied, w

143 r blood flow (PMBF), diffusing capacity, and hyperinflation were also examined.

144 Cyclic recruitment/de-recruitment and tidal hyperinflation were determined as tidal changes in perce

145 Severe emphysema worsens symptoms through hyperinflation, which can be relieved by bronchoscopic l

146 ycopyrronium (IND/GLY) significantly reduced hyperinflation, which translated into improved cardiac f

147 Loss of lung elastic recoil causing hyperinflation with increased TLC and decreased diffusin

148 biting an airway-predominant phenotype (lung hyperinflation without significant emphysema).

149 bjectives: We hypothesized that reduction of hyperinflation would improve cardiac preload in this pat